Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
Alligator Biosci AB, S-22363 Lund, Sweden.;Lund Univ, Dept Immunotechnol, Lund, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
Alligator Biosci AB, S-22363 Lund, Sweden..
Alligator Biosci AB, S-22363 Lund, Sweden..
Show others and affiliations
2017 (English)In: Cancer Immunology and Immunotherapy, ISSN 0340-7004, E-ISSN 1432-0851, Vol. 66, no 1, p. 1-7Article, review/survey (Refereed) Published
Abstract [en]

The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation.

Place, publisher, year, edition, pages
2017. Vol. 66, no 1, p. 1-7
Keywords [en]
Immunotherapy, Tumor-directed immunotherapy, Cancer, Intratumoral, Bispecific antibody, Immuno-oncology
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-318679DOI: 10.1007/s00262-016-1909-3ISI: 000393598500001PubMedID: 27714433OAI: oai:DiVA.org:uu-318679DiVA, id: diva2:1084975
Available from: 2017-03-27 Created: 2017-03-27 Last updated: 2017-11-29Bibliographically approved

Open Access in DiVA

fulltext(532 kB)102 downloads
File information
File name FULLTEXT01.pdfFile size 532 kBChecksum SHA-512
fc0ebae90bc2ce88e8cdb90f201315699dcb513367a1cc3bd95421d01a4c0e077ad8be44b95bc514b1b567a34a06ee2143f42a8d2534d42be7e18b6758e02d79
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Mangsbo, Sara M.Tötterman, Thomas
By organisation
Clinical Immunology
In the same journal
Cancer Immunology and Immunotherapy
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 102 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 495 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf